- Home
- COLL
as 11-03-2025 3:45pm EST
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Upcoming Earnings Alert:
Get ready for potential market movements as Collegium Pharmaceutical Inc. COLL prepares to release earnings report on 06 Nov 2025.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | STOUGHTON |
| Market Cap: | 1.1B | IPO Year: | 2015 |
| Target Price: | $44.25 | AVG Volume (30 days): | 311.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.06 | EPS Growth: | -56.39 |
| 52 Week Low/High: | $23.23 - $39.95 | Next Earning Date: | 11-06-2025 |
| Revenue: | $707,007,000 | Revenue Growth: | 22.61% |
| Revenue Growth (this year): | 21.29% | Revenue Growth (next year): | 3.36% |
Stock Insider Trading Activity of Collegium Pharmaceutical Inc. (COLL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Thomas B | COLL | EVP and Chief Medical Officer | Aug 29 '25 | Sell | $38.42 | 17,478 | $671,576.42 | 70,264 | |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Aug 18 '25 | Sell | $38.21 | 16,389 | $626,171.25 | 103,613 | |
| SANTINI GINO | COLL | N/A | Aug 15 '25 | Sell | $37.19 | 5,405 | $201,018.44 | 95,042 | |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Aug 13 '25 | Sell | $38.03 | 4,861 | $184,880.84 | 103,613 | |
| Rubric Capital Management LP | COLL | N/A | Aug 13 '25 | Sell | $37.85 | 25,000 | $946,250.00 | 3,132,743 | |
| Freund John Gordon | COLL | N/A | Aug 8 '25 | Sell | $34.36 | 11,659 | $400,640.55 | 23,129 |
Latest Collegium Pharmaceutical Inc. News
COLL Breaking Stock News: Dive into COLL Ticker-Specific Updates for Smart Investing
24/7 Wall St.
3 days ago
3 Explosive Stocks With High Short Interest
StockStory
4 days ago
3 Stocks Under $50 That Fall Short
GlobeNewswire
4 days ago
Knight Therapeutics Announces Launch of JORNAY PM™ in Canada
Zacks
4 days ago
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
GlobeNewswire
5 days ago
Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment
GlobeNewswire
21 days ago
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
StockStory
24 days ago
UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know
Insider Monkey
a month ago
Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory
Compare COLL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COLL Collegium Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.